Immunotech Biopharm FY26 H1 net loss narrows 45.8% to RMB 69.87 million

• Immunotech Biopharm reported a first-half loss attributable to owners of RMB 69.87 million, narrowing 45.9% year over year.
• Basic loss per share improved to RMB 0.11 from RMB 0.25 a year earlier.
• Finance costs more than doubled to RMB 21.1 million, driven by higher interest on convertible bonds at maturity.
• Other gains swung to RMB 10.63 million, helped by a RMB 32.14 million fair-value gain on other financial liabilities.
• EAL conditional NDA was terminated; the group is finalizing a confirmatory trial protocol and targets resubmission about 39 months after trial start.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immunotech Biopharm Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12295216), on August 21, 2026, and is solely responsible for the information contained therein.